Login / Signup
Opinion: The optimal use of risk factors to guide palivizumab prophylaxis against severe respiratory syncytial virus infection in moderate-to-late preterm infants.
Bosco Paes
Marcello Lanari
Barry Rodgers-Gray
John Fullarton
Xavier Carbonell-Estrany
Published in:
Frontiers in pediatrics (2024)
Keyphrases
</>
respiratory syncytial virus
preterm infants
risk factors
low birth weight
high intensity
early onset
drug induced